What did UBS change in the BAX analyst rating on February 16, 2026?

On February 16, 2026, UBS maintained a **Neutral** BAX analyst rating and lowered the price target to **$19** from **$21**, citing margin pressure after Q4 2025 results.

How does the UBS Neutral BAX analyst rating affect investors?

UBS’s Neutral suggests limited near-term upside for BAX and signals caution. Investors should watch margins and the 2026 EPS range of **$1.85–$2.05** before increasing positions.

Where can I read the UBS note and Baxter’s earnings details related to the BAX analyst rating?

UBS’s note is summarized by TheFly and Baxter’s earnings call transcript is on Seeking Alpha. See the UBS summary at [TheFly](https://thefly.com/permalinks/entry.php/id4293335/6561286394/BAX-Baxter-price-target-lowered-by--at-UBS-heres-why) and the call at [Seeking Alpha](https://seekingalpha.com/a/

What is Meyka’s current view on BAX and the BAX analyst rating?

Meyka AI rates BAX **B**. The grade reflects benchmark and sector comparisons, growth metrics, and analyst consensus. Meyka flags UBS’s Neutral as cautious given margin risk.

Analyst Ratings

UBS Maintains Neutral on BAX Baxter International Inc. Feb 2026

ByDanny Kontos February 17, 2026February 17, 2026

On February 16, 2026, UBS maintained its Neutral rating on Baxter International Inc. (BAX) and lowered the price target to $19 from $21. The move is the single notable analyst action this week and follows Baxter’s recent Q4 2025 report and guidance for 2026. The BAX analyst rating remains cautious amid margin pressure and a modest 2026 EPS target range of $1.85–$2.05. Investors should view the UBS maintenance as a signaling adjustment, not a directional upgrade or downgrade, and weigh it against Baxter’s fundamentals and sector peers.